Global Market Size, Forecast, and Trend Highlights Over 2025-2037
Tenosynovial Giant Cell Tumor Market size was valued at USD 8.42 billion in 2024 and is set to exceed USD 13.85 billion by 2037, registering over 3.9% CAGR during the forecast period i.e., between 2025-2037. In the year 2025, the industry size of tenosynovial giant cell tumor is evaluated at USD 8.7 billion.
The market will notice this surge primarily due to the rising cases of tenosynovial giant cell tumors in people across the globe. In fact, recently 43 in 1 million people got tenosynovial giant cell tumors. Women are slightly more prone to have tenosynovial giant cell tumors in contrast to men whereas the prevalence of these tumors is majorly shown in young people. People between the age of 25 to 50 have tenosynovial GCT and 1 in 2 people with a bone GCT are in their 30s or 40s.
However, the awareness among people worldwide to address the disease and treat it will further wheel the tenosynovial giant cell tumor market and take it to the expected USD by the end of 2036. A global agreement meeting was carried out on June 21, 2022, in Frankfurt, Germany, including global multidisciplinary sarcoma specialists in cooperation with patient representatives from the Sarcoma Patient Advocacy Global Network (SPAGN) to explain the best clinical practice in TGCT and produce the suggestions exhibited herein. Moreover, recent research made by the National Cancer Institute’s (NCI) branch named Patient-Reported Outcomes Measurement Information System-Physical Function (PROMIS-PF) has shown a treatment journey of D-TGCT patients as a 2-year data-based follow-up and came to know that people internationally are becoming more aware of the disease recently. Most patients suffering from TGCT are young and, although generally not life-forbidding, the disease and its treatment may influence quality of life (QoL).
Tenosynovial Giant Cell Tumor Market: Growth Drivers and Challenges
Growth Drivers
- Increasing Improvement in the Diagnosis - The increasing prevalence and consumer awareness are further increasing the demand for modified diagnosis of TGCT across the planet. An expertized imaging process, MRI (magnetic resonance imaging), is frequently implemented to diagnose a tenosynovial giant cell tumor. A physician or doctor carries a synovial fluid model, which shows the incidence or potential growth of a tenosynovial giant cell tumor. With people affected by tenosynovial giant cell tumors, the synovial fluid frequently discovers blood in the model. However, in particular cases, the microscopic investigation or surgical elimination of damaged tissue is required to ensure the incidence of a tenosynovial giant cell tumor. Moreover, in the upcoming years, multiple developments in the magnetic resonance imaging (MRI) process for modified imaging of tumors will take place and will strengthen the diagnosis system of TGCT more than ever. The ultimate diagnosis test is the tumor biopsy that confirms the prevalence of TGCT in the patients.
- Different Unique and Advanced Treatment Process - Moreover, if untreated or if the tumor persistently reappears, it can result in harm and deteriorate the affected joint and encircling tissues or structures, and thus, different unique and advanced treatment is taking place currently. Surgery is commonly the starting treatment choice. The recent standard of the cure for patients with TGCT is surgical resection of the tumor using surgical kits as totally as possible to limit symptoms and stop joint damage, modify function, and limit the risk of reappearance. Multiple surgical choices for symptomatic TGCT are used nowadays and those are arthroscopy, open surgery, combined arthroscopy, and open surgery total joint replacement, etc.
- Implementation of Modern Radiotherapy - Although massive TGCT cases are commonly cured by surgical treatment, however, for mild and intermediate TGCT radiotherapy is used. Radiotherapy is well-known and widely used to treat TGCT patients. It is usually used before surgery to decrease the tumor or after surgery to wipe out any leftover tumor cells. Intra-articular radiation therapy is mainly utilized for TGCT. This signifies a radioactive element is inserted into the joint to wipe out the tumor. Radiation therapy is utilized with warning in children but it is commonly used in young and elderly people.
Challenges
- The Economical Burden on the Patient's Families - Further, the treatment of tenosynovial giant cell tumors is costly as the drugs that are used to treat the disease are expensive. Currently, it is found that highlights the possibility of under-identified direct healthcare pressure related to TGCT. Patients with TGCT had huge HRU and direct healthcare costs compared with TGCT-free controls. By and large, patients with TGCT were more possibly to ask for medical care in comparison to TGCT-free controls, resulting in around USD 9368 yearly extra healthcare costs. The utilization of both healthcare and non-healthcare products can be translated into an average cost related to TGCT of almost USD 5,329 for the baseline period, where healthcare costs show approximately USD 5,061. TGCT puts a huge pressure on its sufferers, which enhances after one year of follow-up, primarily because of the healthcare resources needed—specifically, surgical techniques. As an outcome, this situation has a high economic influence on healthcare budgets, while the HRQOL of TGCT patients significantly degenerates over time.
- Several Side Effects of The Drugs
- Limited Research in This Field
Tenosynovial Giant Cell Tumor Market: Key Insights
| Report Attribute | Details |
|---|---|
|
Base Year |
2024 |
|
Forecast Year |
2025-2037 |
|
CAGR |
3.9% |
|
Base Year Market Size (2024) |
USD 8.42 billion |
|
Forecast Year Market Size (2037) |
USD 13.85 billion |
|
Regional Scope |
|
Tenosynovial Giant Cell Tumor Market Segmentation
Treatment (Drug Therapy, Radiation Therapy, Surgical Procedures)
The surgical procedures segment is anticipated to increase at the fastest CAGR at the time of the forecast period and have around 60% share of the tenosynovial giant cell tumor market. This segment is set to have the largest share due to its frequent use for diagnosing and treating tenosynovial giant cell tumors. Moreover, between 2002 to 2023, 144 patients with D-TGCT experienced surgery as basic treatment with a base age of 39 years. The knee (72%) was the most influenced joint. For 86 patients (60%), surgery was their first TGCT-related treatment and they were reportedly cured. After surgical procedures, high repetition rates are known, with the localized type up to 50% and the diffuse type up to 92%. In massive cases of tenosynovial giant cell tumor, where MRI cannot infer the outcome or offer a verification receipt associating the happening of tenosynovial giant cell tumor in a person, surgical procedures are executed. A biopsy of influenced tissue is studied through surgery to make sure the case of tenosynovial giant cell tumor. Similarly, surgical procedures are frequently executed in the therapy of tenosynovial giant cell tumors and pigmented villonodular synovitis bit by bit revises itself, which takes to repetition post-surgery.
Disease Type (Localized Giant Cell Tumor, Diffuse Giant Cell Tumor)
The localized giant cell tumor segment is projected to control the tenosynovial giant cell tumor market during the forecast period and hold a revenue share of almost 70%. The localized giant cell tumor segment is set to grow and has the largest share as this type of TGCT is more prevalent in people worldwide. For instance, one of the more all-inclusive studies was by Mastboom et al comprising 4,503 cases of TGCT. They noticed that the abundance of tumors was situated locally in the digits (68%) followed by those explained as localized-border (knee, wrist, elbow, hip, etc; 23%), and the rest 9% were diffuse-type tumors. Localized TGCTs emerge chiefly in the hand with roughly 85% of the tumors emerging in the digits. However, the tumors can come at other sites, like the knee, wrist, ankle/foot, and very rarely the elbow or the hip. To understand the patient has localized TGCTs the best process is to make medical imaging.
Our in-depth analysis of the global tenosynovial giant cell tumor market includes the following segments:
|
Disease Type |
|
|
Treatment |
|
|
End-use |
|
Vishnu Nair
Head - Global Business DevelopmentCustomize this report to your requirements — connect with our consultant for personalized insights and options.
Tenosynovial Giant Cell Tumor Industry - Regional Synopsis
North American Market Forecast
North America industry is likely to dominate majority revenue share of 43% by 2037, driven by manufacturing and approvals of new novel drugs for tenosynovial giant cell tumors in the region. North America is set to hold this position in the coming years because of the inventions and approvals of new novel drugs for tenosynovial giant cell tumors in the region. For instance, on March 23, 2023, Evkeeza is an angiopoietin-like 3 (ANGPTL3) inhibitor shown as a supplement to other low-density lipoprotein-cholesterol (LDL-C) reducing treatments for the cure of adult and pediatric patients, aged 5 years and older, with homozygous familial hypercholesterolemia (HoFH). Evkeeza is a fully human monoclonal antibody that works by binding to and blocking the function of angiopoietin-like 3 (ANGPTL3), a protein that plays a key role in lipid metabolism. Evkeeza is the first FDA-licensed ANGPTL3 inhibitor. Evkeeza is directed via intravenous mixture once a month (every 4 weeks).
European Market
However, the Europe tenosynovial giant cell tumor market is poised to grow significantly by the end of 2036. The reason for the growth lies majorly in the government initiatives of the European countries to have novel drugs on TGCT. Recently, SynOx Therapeutics Limited declared its novel monoclonal antibody, emactuzumab, in progress for the treatment of tenosynovial giant cell tumor (TGCT) and other diseases, has been approved as an orphan medicinal material for both localized and diffuse types of the disease by the European Medicines Agency (EMA).
Companies Dominating the Tenosynovial Giant Cell Tumor Landscape
- Abbisko Therapeutics
- Company Overview
- Business Planning
- Main Product Offerings
- Financial Execution
- Main Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Ammax Bio Inc.
- HUTCHMED
- SynOx Therapeutics Limited
- Deciphera Pharmaceuticals Inc.
- F. Hoffmann-La Roche Ltd
- Novartis AG
- Amgen Inc.
- Celleron Therapeutics Limited
- Takeda Pharmaceutical Company Limited.
Recent Developments
- Abbisko Therapeutics declared that the newest results of the Phase Ib study of its CSF-1R inhibitor Pimicotinib (ABSK021) in curing patients with advanced tenosynovial giant cell tumor ("TGCT"), was published at the 2023 American Society of Clinical Oncology ("ASCO") yearly meeting that took place in Chicago, USA from June 2 to June 6, 2023.
- Ammax Bio Inc. declared that the European Medicines Agency (EMA) has approved AMB-05X Priority Medicines (PRIME) designation for the cure of tenosynovial giant cell tumor (TGCT). AmMax Bio delivered positive Phase II information for the novel local management of AMB-05X in patients with TGCT at the Connective Tissue Oncology Society meeting in November 2022. The efficiency information across multiple clinical endpoints and a favorable protection profile support the possibility of AMB-05X as a best-in-class treatment for the therapy of TGCT irrespective of surgical reputability.
- Report ID: 5449
- Published Date: Jan 03, 2025
- Report Format: PDF, PPT
- Get detailed insights on specific segments/region
- Inquire about report customization for your industry
- Learn about our special pricing for startups
- Request a demo of the report’s key findings
- Understand the report’s forecasting methodology
- Inquire about post-purchase support and updates
- Ask About Company-Level Intelligence Additions
Have specific data needs or budget constraints?
Inquiry Before BuyingFrequently Asked Questions (FAQ)
FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.
Connect with our Expert
